These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30674687)

  • 61. Epidemiology of anogenital warts and cancer.
    Franco EL
    Obstet Gynecol Clin North Am; 1996 Sep; 23(3):597-623. PubMed ID: 8869948
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis.
    Husein-ElAhmed H
    Int J STD AIDS; 2020 Jun; 31(7):606-612. PubMed ID: 32438856
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.
    Giuliano AR; Tortolero-Luna G; Ferrer E; Burchell AN; de Sanjose S; Kjaer SK; Muñoz N; Schiffman M; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 10(0 10):K17-28. PubMed ID: 18847554
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
    Gilbert DC; Wakeham K; Langley RE; Vale CL
    Br J Cancer; 2019 Jan; 120(2):256-268. PubMed ID: 30482913
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The HPV infection in males: an update.
    Giraldi G; De Luca d'Alessandro E
    Ann Ig; 2012; 24(6):497-506. PubMed ID: 23234187
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Human Papillomavirus infection and vaccination: knowledge and attitudes of Italian general practitioners].
    Signorelli C; Odone A; Pezzetti F; Spagnoli F; Visciarelli S; Ferrari A; Camia P; Latini C; Ciorba V; Agodi A; Barchitta M; Scotti S; Misericordia P; Pasquarella C
    Epidemiol Prev; 2014; 38(6 Suppl 2):88-92. PubMed ID: 25759351
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
    Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER
    Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503
    [TBL] [Abstract][Full Text] [Related]  

  • 68. US Health Care Clinicians' Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Vaccination: A Qualitative Systematic Review.
    Rosen BL; Shepard A; Kahn JA
    Acad Pediatr; 2018 Mar; 18(2S):S53-S65. PubMed ID: 29502639
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
    Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J
    BMJ; 2015 May; 350():h2016. PubMed ID: 25985328
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Determining the cost of genital warts: a study from Ireland.
    Dee A; Howell F; O'Connor C; Cremin S; Hunter K
    Sex Transm Infect; 2009 Sep; 85(5):402-3. PubMed ID: 19004863
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.
    Fu S; Fokom Domgue J; Chan W; Zhao B; Ramondetta LM; Lairson DR
    J Low Genit Tract Dis; 2019 Apr; 23(2):102-109. PubMed ID: 30907776
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature.
    Taylor S; Bunge E; Bakker M; Castellsagué X
    BMC Infect Dis; 2016 Jun; 16():293. PubMed ID: 27301867
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vaccines for preventing HPV-related anogenital infection and neoplasia.
    Ferris DG
    J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidemiological and economic burden of potentially HPV-related cancers in France.
    Abramowitz L; Lacau Saint Guily J; Moyal-Barracco M; Bergeron C; Borne H; Dahlab A; Bresse X; Uhart M; Cancalon C; Catella L; Bénard S
    PLoS One; 2018; 13(9):e0202564. PubMed ID: 30235216
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases.
    Suijkerbuijk AW; Donken R; Lugnér AK; de Wit GA; Meijer CJ; de Melker HE; Bogaards JA
    Expert Rev Vaccines; 2017 Apr; 16(4):361-375. PubMed ID: 27807989
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018.
    Chesson HW; Laprise JF; Brisson M; Martin D; Ekwueme DU; Markowitz LE
    Sex Transm Dis; 2021 Apr; 48(4):278-284. PubMed ID: 33492104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.